Create
Query
event_store.db
—
signals
actions
agent_runs
approvals
artifacts
attention_candidates
commitments
constraints
conversation_compaction
conversation_state
conversation_turns
dead_letters
decisions
deliveries
effects
email_messages
email_reply_drafts
email_threads
entities
entity_aliases
entity_tags
episode_context_index
episodes
event_subjects
events
events_archive
fact_sources
facts
inbox_items
inbox_links
intel_narrative_members
intel_narratives
jobs
leader_leases
links
memory_candidates
memory_embeddings
memory_items
memory_items_fts
(v)
memory_items_fts_config
memory_items_fts_data
memory_items_fts_idx
opportunity_memory
pending_interactions
proposal_sources
proposals
reminders
schedules
schema_migrations
signal_candidates
signal_fps
signals
sms_conversations
sms_messages
sms_reply_drafts
source_cursors
sources
sqlite_sequence
sqlite_stat1
stream_cursors
threads
watchers
Toggle helper tables
memory_items_fts_content
memory_items_fts_docsize
memory_items_fts_segdir
memory_items_fts_segments
memory_items_fts_stat
Structure
Content
Query
Insert
Drop
Import
Export
Update row sig_7f8b8b07cb14 in signals
id
sig_7f8b8b07cb14
Primary key.
TEXT
event_id
478703
TEXT NOT NULL
watcher_id
NULL
TEXT
signal_type
discovery_sec_filing_delta
TEXT NOT NULL
value
{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/2036042/0000947871-26-000458.txt","as_of":"2026-04-22T03:03:32.063787+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/2036042/0000947871-26-000458.txt","company":"Sionna Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/2036042/0000947871-26-000458.txt","article_chars":3698,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_3fe08b08d079758f","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/2036042/0000947871-26-000458.txt","content_type":"text/plain","enriched_at":"2026-04-22T03:29:17.283769+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/2036042/0000947871-26-000458.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/2036042/0000947871-26-000458.txt","source_event_id":"evt_52df221f4600","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"a0e1a3f592970802","kind":"sec_filing","published_at":"20260421","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-17","2026-04-18","2026-04-21","2026-04-22T03:03:32.063787+00:00"],"entities":[{"asset_class":"equity","name":"Sionna Therapeutics, Inc.","relevance":"high","symbol":"SION","type":"issuer"},{"asset_class":"equity","name":"OrbiMed Advisors LLC","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"equity","name":"OrbiMed Capital GP VIII LLC","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"equity","name":"OrbiMed Private Investments VIII, LP (OPI VIII)","relevance":"medium","symbol":"","type":"entity_relationship"},{"asset_class":"equity","name":"Carl L. Gordon","relevance":"medium","symbol":"","type":"individual"},{"asset_class":"equity","name":"Sven H. Borho","relevance":"medium","symbol":"","type":"individual"},{"asset_class":"equity","name":"W. Carter Neild","relevance":"medium","symbol":"","type":"individual"},{"asset_class":"equity","name":"Peter A. Thompson","relevance":"low","symbol":"","type":"individual"}],"event_type":"listing","information_gaps":["The provided text does not explicitly label the transaction type (e.g., sale vs purchase) beyond the statement that \u201cThese securities were sold pursuant to a 10b5-1 plan,\u201d and it does not clearly map each numeric line to a specific transaction type (e.g., sale vs other) beyond the generic \u201csold\u201d statement.","The \u201cSION filed 4\u201d headline is not fully corroborated in the extracted text beyond the issuer name and the presence of Form 4; the exact headline text content is not included in the article text.","No explicit \u201cchange vs prior known state\u201d is provided in the supplied text (no prior Form 4 baseline or comparison data is included)."],"key_facts":["SEC accession document shows CONFORMED SUBMISSION TYPE: 4 and CONFORMED PERIOD OF REPORT: 20260417, FILED AS OF DATE: 20260421.","Reporting persons include OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, both listed as Form 4 reporting owners for issuer Sionna Therapeutics, Inc. (SION).","The filing states: \u201cThese securities were sold pursuant to a 10b5-1 plan.\u201d","The filing states the securities are held of record by OrbiMed Private Investments VIII, LP (\u201cOPI VIII\u201d).","The filing states OrbiMed Capital GP VIII LLC is the general partner of OPI VIII and OrbiMed Advisors LLC is the managing member of GP VIII, and that they may be deemed to have voting and investment power with respect to shares held by OPI VIII.","The filing states that Carl L. Gordon, Sven H. Borho, and W. Carter Neild exercise investment and voting power through a management committee and each disclaims beneficial ownership of the shares held by OPI VIII.","The filing states it is jointly filed by OrbiMed Advisors and GP VIII and includes signatures dated 2026-04-21 by Carl L. Gordon (Member of OrbiMed Advisors LLC and Member of OrbiMed Capital GP VIII LLC).","The filing includes a statement that a representative (Peter A. Thompson) has been designated to serve on the issuer\u2019s board of directors."],"numeric_claims":[{"label":"Conformed period of report","value":"20260417"},{"label":"Filed as of date","value":"20260421"},{"label":"Issuer fiscal year end","value":"1231"},{"label":"Common stock transaction date shown (first line)","value":"2026-04-17"},{"label":"Common stock transaction date shown (second line)","value":"2026-04-18"},{"label":"Common stock quantity shown (first line)","value":"52397"},{"label":"Common stock price shown (first line)","value":"44.68"},{"label":"Common stock quantity shown (second line)","value":"2948"},{"label":"Common stock price shown (second line)","value":"44.52"}],"primary_claim":"Form 4 for Sionna Therapeutics, Inc. was filed on 2026-04-21 (covering period of report 2026-04-17) reporting common stock transactions by OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC under a 10b5-1 plan.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Sionna Therapeutics, Inc. (SION) reported a Form 4 filed on 2026-04-21 covering common stock transactions by OrbiMed-related reporting persons under a 10b5-1 plan. The filing indicates the shares are held through OrbiMed Private Investments VIII, LP and that OrbiMed Advisors/GP VIII may be deemed to have beneficial ownership, with certain individuals disclaiming beneficial ownership.","topics":["SEC Form 4","insider/beneficial ownership","10b5-1 plan","OrbiMed","common stock transactions"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Sionna Therapeutics, Inc. \u00b7 Filed 20260421","ticker":"SION","tickers":["SION"],"title":"SION filed 4","url":"https://www.sec.gov/Archives/edgar/data/2036042/0000947871-26-000458.txt"}
TEXT NOT NULL
threshold
NULL
TEXT
direction
NULL
TEXT
severity
NULL
TEXT
window
NULL
TEXT
source
discovery_sec_filings
TEXT NOT NULL
reason_trace
{"_evidence_event_ids":["evt_52df221f4600"]}
TEXT
dedupe_key
signal_enriched:discovery_sec_filing_delta:b6ebfc3d7047afe3
TEXT NOT NULL
throttle_s
INTEGER (default 0
created_at
2026-04-22T03:03:32.063787+00:00
TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')
Update
Cancel